Medtronic plc (MDT)
Overview
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-11-18 |
| Earnings Call | 2025-11-18 |
| Avg EPS Estimate | 1.3141 |
| Low EPS Estimate | 1.31 |
| High EPS Estimate | 1.32 |
| Revenue | |
| Avg Revenue Forecast | 8,855,021,160 |
| Low Revenue Forecast | 8,750,000,000 |
| High Revenue Forecast | 8,911,000,000 |
MDT Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $8,120,999,936 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 1.248 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 2.014 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $28,608,999,424 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
MDT Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $9,445,999,616 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $7,145,999,872 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $4,464,875,008 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 65.38% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 18.69% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 13.63% | Net profit margin, which reflects overall profitability. |
MDT Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 59.44% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $28,608,999,424 | Used together with cash and EBITDA to assess debt-paying ability. |
MDT Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 8.40% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 1.30% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for MDT (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $90.4 | Latest stock trading price |
| Price Target (High) | $115 | Analyst highest expected price |
| Price Target (Low) | $81 | Analyst lowest expected price |
| Price Target (Average) | $101.13 | Average target price across analysts |
| Price Target (Median) | $102 | Median of target prices |
| Average Rating Score | 2.19 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | buy | Consensus rating |
| Analyst Coverage Count | 26 | Number of analysts providing estimates |
| Cash Holdings | $8,120,999,936 | Total cash held by the company |
| Cash per Share | $6.33 | Cash value per outstanding share |
| Total Debt | $28,608,999,424 | Company's total debt |
| Quick Ratio | 1.248 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 2.014 | Overall short-term liquidity |
| Debt/Equity Ratio | 59.44% | Leverage ratio: Debt / Equity |
| EBITDA | $9,445,999,616 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $34,200,000,512 | Total company revenue |
| Revenue per Share | $26.663 | Total revenue divided by shares outstanding |
| Gross Profit | 65.38% | Revenue minus cost of goods sold |
| Return on Assets | 4.57% | Net income / Total assets |
| Return on Equity | 9.74% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 1.30% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 8.40% | Year-over-year revenue growth |
| Gross Margin | 65.38% | Gross profit / Total revenue |
| EBITDA Margin | 27.62% | EBITDA / Revenue |
| Operating Margin | 18.69% | Operating income / Revenue |
| Profit Margin | 13.63% | Net income / Revenue |
| Free Cash Flow | $4,464,875,008 | Cash left after capital expenditures |
| Operating Cash Flow | $7,145,999,872 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |